-
2023.10.30
VOLUNTARY ANNOUNCEMENT
KEN-VALVE REGISTRATION APPLICATION ENTERS NMPA PRIORITY
APPROVAL PROCESS
-
2023.10.20
VOLUNTARY ANNOUNCEMENT
LUX-VALVE PLUS SUCCESSFULLY COMPLETES A SERIES OF
FEE-FOR-SERVICE COMPASSIONATE USE TREATMENTS
IN THE ASIA-PACIFIC REGION
-
2023.10.19
VOLUNTARY ANNOUNCEMENT RELEASE OF THE RESULTS OF THE MULTICENTER CLINICAL TRIAL OF LUX-VALVE PLUS AT THE 2023 TCT IN THE U.S.
-
2023.10.11
VOLUNTARY ANNOUNCEMENT
REGISTRATION APPLICATION FOR
KEN-VALVE ACCEPTED BY THE NMPA
-
2023.10.10
VOLUNTARY ANNOUNCEMENT
LUX-VALVE PLUS SELECTED FOR THE EXPERT PANEL
SCIENTIFIC ADVICE PILOT
-
2023.10.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
-
2023.09.18
2023 Interim Report
-
2023.09.18
VOLUNTARY ANNOUNCEMENT ENROLLED IN FDA TOTAL PRODUCT LIFE CYCLE ADVISORY PROGRAM (TAP) PILOT
-
2023.09.05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
-
2023.08.28
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023